Published in Invest Ophthalmol Vis Sci on August 21, 2008
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn (2010) 2.48
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA (2014) 2.48
SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res (2011) 2.46
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet (2013) 2.20
Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev (2011) 1.98
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer (2009) 1.93
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep (2014) 1.73
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol (2010) 1.65
Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol (2008) 1.44
Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol (2013) 1.43
The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res (2012) 1.39
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Metastatic uveal melanoma: biology and emerging treatments. Cancer J (2012) 1.27
Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res (2012) 1.20
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol (2014) 1.13
Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol (2013) 1.11
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One (2012) 1.09
Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci (2011) 1.07
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Fam Cancer (2010) 1.03
Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res (2010) 1.03
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther (2012) 1.03
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Uveal melanoma. J Skin Cancer (2011) 0.98
Influence of immune privilege on ocular tumor development. Ocul Immunol Inflamm (2010) 0.97
Molecular nevogenesis. Dermatol Res Pract (2011) 0.97
Molecular pathology of uveal melanoma. Eye (Lond) (2012) 0.94
Genomic, prognostic, and cell-signaling advances in uveal melanoma. Am Soc Clin Oncol Educ Book (2013) 0.94
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res (2016) 0.93
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther (2014) 0.91
A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology (2014) 0.91
Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis (2015) 0.91
The pathology of ocular cancer. Eye (Lond) (2012) 0.91
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
A comparative transcriptomic analysis of uveal melanoma and normal uveal melanocyte. PLoS One (2011) 0.88
Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. JAMA Ophthalmol (2016) 0.87
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget (2016) 0.85
Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol (2013) 0.85
miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications. Cancer Biol Ther (2015) 0.84
Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med (2013) 0.84
Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene (2014) 0.83
Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer (2013) 0.83
High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.82
Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One (2014) 0.82
Molecular bases of cutaneous and uveal melanomas. Patholog Res Int (2011) 0.81
Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res (2015) 0.81
The G protein α chaperone Ric-8 as a potential therapeutic target. Mol Pharmacol (2014) 0.80
BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma. FEBS Open Bio (2012) 0.79
Lack of GNAQ germline mutations in uveal melanoma patients with high risk for hereditary cancer predisposition. Fam Cancer (2011) 0.78
Characterization of three cell lines derived from fine needle biopsy of choroidal melanoma with metastatic outcome. Mol Vis (2011) 0.78
Lack of GNAQ and GNA11 Germ-Line Mutations in Familial Melanoma Pedigrees with Uveal Melanoma or Blue Nevi. Front Oncol (2013) 0.78
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism. PLoS One (2015) 0.78
Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol (2016) 0.77
Drosophila as a Potential Model for Ocular Tumors. Ocul Oncol Pathol (2015) 0.77
Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul Oncol Pathol (2014) 0.76
Repression of genes involved in melanocyte differentiation in uveal melanoma. Mol Vis (2012) 0.76
Antibodies reacting with Simian Virus 40 capsid protein mimotopes in serum samples from patients affected by uveal melanoma. J Hematol Oncol (2014) 0.76
Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer (2011) 0.76
Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese. PLoS One (2014) 0.76
The biology of uveal melanoma. Cancer Metastasis Rev (2017) 0.75
Preliminary results of proton radiotherapy for choroidal melanoma - the Kraków experience. Contemp Oncol (Pozn) (2014) 0.75
Uveal Melanoma Patient-Derived Xenografts. Ocul Oncol Pathol (2015) 0.75
The genetics of uveal melanoma: current insights. Appl Clin Genet (2016) 0.75
Ocular tumors: Triumphs, challenges and controversies. Saudi J Ophthalmol (2013) 0.75
Clinical application of genetic testing for posterior uveal melanoma. Int J Retina Vitreous (2016) 0.75
A melanoma subtype: uveal melanoma. J Am Acad Dermatol (2011) 0.75
A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents. Case Rep Oncol Med (2016) 0.75
Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQ(Q209L)-driven melanoma. Oncogenesis (2016) 0.75
Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish. Oncotarget (2016) 0.75
Uveal Melanoma: Current Trends in Diagnosis and Management. Turk J Ophthalmol (2016) 0.75
Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. Clin Exp Metastasis (2014) 0.75
Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints. Front Oncol (2017) 0.75
BRAF V600E-dependent role of autophagy in uveal melanoma. J Cancer Res Clin Oncol (2016) 0.75
Focus on cutaneous and uveal melanoma specificities. Genes Dev (2017) 0.75
Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin? Trends Cancer (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem (2000) 5.84
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res (2004) 3.83
Effects of G-protein mutations on skin color. Nat Genet (2004) 3.08
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res (2003) 2.18
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res (2007) 2.15
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res (2006) 2.03
The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol (2000) 1.76
Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res (2007) 1.71
Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res (2003) 1.70
Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem (2007) 1.66
Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci (2001) 1.57
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res (2008) 1.54
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem (2003) 1.53
The genome and epigenome of malignant melanoma. APMIS (2007) 1.36
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) (2007) 1.35
Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest (2003) 1.33
Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol (2000) 1.29
Sphingosine-1-phosphate decreases melanin synthesis via sustained ERK activation and subsequent MITF degradation. J Cell Sci (2003) 1.29
Lack of BRAF mutations in uveal melanoma. Cancer Res (2003) 1.27
Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci (2008) 1.22
Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol (2005) 1.19
Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res (2008) 1.18
Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. J Biol Chem (2006) 1.16
Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci (2006) 1.11
Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci (2005) 1.08
Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer (2005) 1.06
Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci (1993) 1.05
The T1799A BRAF mutation is present in iris melanoma. Invest Ophthalmol Vis Sci (2007) 1.05
Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res (2000) 1.00
Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. Cancer Genet Cytogenet (1996) 0.99
Rb at the interface between cell cycle and apoptotic decisions. Curr Mol Med (2006) 0.98
Iris melanoma. Arch Pathol Lab Med (2008) 0.91
Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch (2006) 0.91
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
Pathogenesis and therapy of psoriasis. Nature (2007) 6.94
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology (2012) 4.61
Completing the map of human genetic variation. Nature (2007) 4.38
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res (2004) 3.83
Direct genomic selection. Nat Methods (2005) 3.61
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet (2002) 3.09
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res (2011) 2.54
An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn (2010) 2.48
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
Genomics: guilt by association. Nature (2007) 2.27
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet (2013) 2.20
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res (2007) 2.15
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist (2011) 2.05
Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res (2006) 2.03
Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol (2004) 1.92
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol (2004) 1.89
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res (2007) 1.71
Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol (2003) 1.67
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res (2013) 1.67
Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet (2009) 1.58
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res (2008) 1.54
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol (2011) 1.50
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol (2009) 1.50
Risk factors for metastasis in retinoblastoma. Surv Ophthalmol (2002) 1.49
Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol (2008) 1.44
Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab (2013) 1.42
Two novel point mutations in the long-range SHH enhancer in three families with triphalangeal thumb and preaxial polydactyly. Am J Med Genet A (2007) 1.41
Psoriasis genetics: breaking the barrier. Trends Genet (2010) 1.38
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
Efficient high-throughput resequencing of genomic DNA. Genome Res (2003) 1.37
Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res (2008) 1.36
New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol (2009) 1.35
DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res (2005) 1.30
A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res (2008) 1.26
A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One (2011) 1.25
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
Asymmetric lower-limb malformations in individuals with homeobox PITX1 gene mutation. Am J Hum Genet (2008) 1.21
Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol Diagn (2006) 1.20
Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol (2005) 1.19
Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res (2008) 1.18
Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol (2005) 1.14
A transmission disequilibrium test for general pedigrees that is robust to the presence of random genotyping errors and any number of untyped parents. Eur J Hum Genet (2004) 1.13
Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol (2014) 1.13
Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol (2013) 1.11
Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol (2005) 1.10
Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. PLoS Genet (2012) 1.10
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci (2005) 1.08
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer (2013) 1.04
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. J Invest Dermatol (2008) 1.04
Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol (2011) 1.04
Psoriasis genetics: the way forward. J Invest Dermatol (2004) 1.03
Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina (2011) 1.03
Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. Am J Med (2002) 1.02
Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res (2012) 1.01
Uveal melanoma: molecular pattern, clinical features, and radiation response. Am J Ophthalmol (2012) 1.01
Molecular genetics of uveal melanoma. Curr Eye Res (2003) 1.00
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Rb at the interface between cell cycle and apoptotic decisions. Curr Mol Med (2006) 0.98
Distinguishing torpedo maculopathy from similar lesions of the posterior segment. Ophthalmic Surg Lasers Imaging Retina (2014) 0.98
Carriers of rare missense variants in IFIH1 are protected from psoriasis. J Invest Dermatol (2010) 0.97